Plasma and Intrapulmonary Pharmacokinetics, and Dosage Regimen Optimization of Linezolid for Treatment of Gram-Positive Cocci Infections in Patients with Pulmonary Infection After Cerebral Hemorrhage

References

• Gregório T, Pipa S, Cavaleiro P, et al. original intracerebral hemorrhage score for the prediction of short-term mortality in cerebral hemorrhage: systematic review and meta-analysis. Crit Care Med. 2019;47(6):857–864. doi:10.1097/ccm.0000000000003744
   Web of Science ®Google Scholar
• Diener H, Hankey G. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage: JACC focus seminar. J Am Coll Cardiol. 2020;75(15):1804–1818. doi:10.1016/j.jacc
   PubMed Web of Science ®Google Scholar
• Kato H, Hagihara M, Asai N, et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2021;24:98–105. doi:10.1016/j.jgar.2020
   PubMed Web of Science ®Google Scholar
• Kalil A, Metersky M, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63(5):e61–e111. doi:10.1093/cid/ciw353
   PubMed Web of Science ®Google Scholar
• Fernández-Barat L, Motos A, Panigada M, et al. Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. Crit Care. 2019;23(1):251. doi:10.1186/s13054-019-2523-5
   Web of Science ®Google Scholar
• Huon J, Boutoille D, Caillon J, et al. Linezolid versus vancomycin cost in the treatment of staphylococcal pneumonia. Med Mal Infect. 2020;50(3):252–256. doi:10.1016/j.medmal.2019.07.012
   Web of Science ®Google Scholar
• Collins C, Schwemm A. Linezolid versus vancomycin in the empiric treatment of nosocomial pneumonia: a cost-utility analysis incorporating results from the ZEPHyR trial. Value Health. 2015;18(5):614–621. doi:10.1016/j.jval.2015.04.007
   PubMed Web of Science ®Google Scholar
• Hashemian S, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018;12:1759–1767. doi:10.2147/dddt.S164515
   PubMed Web of Science ®Google Scholar
• Zahedi Bialvaei A, Rahbar M, Yousefi M, et al. Linezolid: a promising option in the treatment of gram-positives. J Antimicrob Chemother. 2017;72(2):354–364. doi:10.1093/jac/dkw450
   Web of Science ®Google Scholar
• Chen H, Du Y, Xia Q, et al. Role of linezolid combination therapy for serious infections: review of the current evidence. Eur J Clin Microbiol Infect Dis. 2020;39(6):1043–1052. doi:10.1007/s10096-019-03801-x
   PubMed Web of Science ®Google Scholar
• Vardakas K, Kioumis I, Falagas M. Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metab. 2009;10(1):2–12. doi:10.2174/1389200097870
   Web of Science ®Google Scholar
• Baijnath S, Shobo A, Bester L, et al. Neuroprotective potential of linezolid: a quantitative and distribution study via mass spectrometry. J Mol Histol. 2016;47(4):429–435. doi:10.1007/s10735-016-9685-0
   Web of Science ®Google Scholar
• Wen S, Zhang T, Yu X, et al. Bone penetration of linezolid in osteoarticular tuberculosis patients of China. Int J Infect Dis. 2021;103:364–369. doi:10.1016/j.ijid.2020.11.203
   PubMed Web of Science ®Google Scholar
• Dilworth T, Beck E, Pedersen R, et al. High rate of linezolid intermediate susceptibility and resistance among enteric vancomycin-resistant Enterococcus (VRE) recovered from hospitalized patients actively screened for VRE colonization. Infect Control Hosp Epidemiol. 2019;40(7):821–822. doi:10.1017/ice.2019.116
   Web of Science ®Google Scholar
• Trang M, Dudley M, Bhavnani S. Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection. Curr Opin Pharmacol. 2017;36:107–113. doi:10.1016/j.coph.2017.09.009
   PubMed Web of Science ®Google Scholar
• Song X, Zeng M, Wu Y, et al. Competence mining of vancomycin (VAN) in the management of infections due to bacterial strains with high VAN minimum inhibitory concentrations (MICs): a novel dosing strategy based on pharmacokinetic/pharmacodynamic modeling. Front Microbiol. 2021;12:649757. doi:10.3389/fmicb.2021.649757
   PubMed Web of Science ®Google Scholar
• Beredaki M, Georgiou P, Siopi M, et al. Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model. J Antimicrob Chemother. 2020;75(1):140–148. doi:10.1093/jac/dkz425
   Web of Science ®Google Scholar
• Leng B, Yan G, Wang C, et al. Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline. J Glob Antimicrob Resist. 2021;25:315–322. doi:10.1016/j.jgar.2021.04.006
   PubMed Web of Science ®Google Scholar
• Yang M, Zhao L, Wang X, et al. Population pharmacokinetics and dosage optimization of linezolid in critically ill pediatric patients. Antimicrob Agents Chemother. 2021;65(5):e02504–e02520. doi:10.1128/aac.02504-20
   Web of Science ®Google Scholar
• Zhao W, Kong L, Wu C, et al. Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains. Eur J Clin Pharmacol. 2021;77(1):79–86. doi:10.1007/s00228-020-02978-x
   Web of Science ®Google Scholar
• Mokline A, Gharsallah L, Rahmani I, et al. Pharmacokinetics and pharmacodynamics of Linezolid in burn patients. Ann Burns Fire Disasters. 2018;31(2):118–121.
   Google Scholar
• Blackman A, Jarugula P, Nicolau D, et al. Evaluation of linezolid pharmacokinetics in critically ill obese patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2021;65(2):e01619–e01620. doi:10.1128/aac.01619-20
   Web of Science ®Google Scholar
• Simon P, Busse D, Petroff D, et al. Linezolid concentrations in plasma and subcutaneous tissue are reduced in obese patients, resulting in a higher risk of underdosing in critically ill patients: a controlled clinical pharmacokinetic study. J Clin Med. 2020;9(4):1067. doi:10.3390/jcm9041067
   Web of Science ®Google Scholar
• Barrasa H, Soraluce A, Usón E, et al. Impact of augmented renal clearance on the pharmacokinetics of linezolid: advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. Int J Infect Dis. 2020;93:329–338. doi:10.1016/j.ijid
   PubMed Web of Science ®Google Scholar
• Wu X, Tang Y, Zhang X, et al. Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation. Drug Des Devel Ther. 2018;12:1679–1684. doi:10.2147/DDDT.S168757
   PubMed Web of Science ®Google Scholar
• Barrasa H, Soraluce A, Isla A, et al. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: influence of residual renal function on PK/PD target attainment. J Crit Care. 2019;50:69–76. doi:10.1016/j.jcrc.2018.11.016
   PubMed Web of Science ®Google Scholar
• Tietjen A, Kroemer N, Cattaneo D, et al. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients. Br J Clin Pharmacol. 2021;88(4):1835–1844. doi:10.1111/bcp.15102doi:10.1111/bcp.15102
   Web of Science ®Google Scholar
• Rodríguez-Gascón A, Aguirre-Quiñonero A, Aspiazu M, et al. Pharmacokinetic/pharmacodynamic analysis of tedizolid phosphate compared to linezolid for the treatment of infections caused by gram-positive bacteria. Antibiotics. 2021;10(7):755. doi:10.3390/antibiotics10070755
   Web of Science ®Google Scholar
• Wang X, Wang Y, Yao F, et al. Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients: a multicenter, prospective, open-label, observational study. Drug Des Devel Ther. 2021;15:2129–2141. doi:10.2147/dddt.S303497
   Web of Science ®Google Scholar
• Dehghanyar P, Bürger C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother. 2005;49(6):2367–2371. doi:10.1128/aac.49.6.2367-2371
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhu Z, Chen Z, et al. Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction. Antimicrob Agents Chemother. 2020;64(6):e00133–e00120. doi:10.1128/aac.00133-20
   PubMed Web of Science ®Google Scholar
• Saeed F, Adil MM, Piracha BH, et al. Acute renal failure worsens in-hospital outcomes in patients with intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2015;24(4):789–794. doi:10.1016/j.jstrokecerebrovasdis.2014.11.012
   Web of Science ®Google Scholar
• Dryden M, Andrasevic A, Bassetti M, et al. A European survey of antibiotic management of methicillin- resistant Staphylococcus aureus infection: current clinical opinion and practice. Clin Microbiol Infect. 2010;16(Suppl1):3–30. doi:10.1111/j.1469-0691.2010.03135.x
   Web of Science ®Google Scholar
• De Pascale G, Fortuna S, Tumbarello M, et al. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Med. 2015;41(1):103–110. doi:10.1007/s00134-014-3550-y
   PubMed Web of Science ®Google Scholar
• Dryden M. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(Suppl4):iv7–iv15. doi:10.1093/jac/dkr072
   Web of Science ®Google Scholar
• Brown N, Brown E. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. J Antimicrob Chemother. 2021;76(6):1377–1378. doi:10.1093/jac/dkab
   Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove S, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–e55. doi:10.1093/cid/ciq146
   PubMed Web of Science ®Google Scholar
• Gilbert DN, Chambers HF, Eliopoulos GM. The Sanford Guide to Antimicrobial Therapy 2020. 50th ed. Sperryville: Antimicrobial Therapy; 2020.
   Google Scholar
• Rao G, Konicki R, Cattaneo D, et al. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2020;42(1):83–92. doi:10.1097/ftd.0000000000000
   PubMed Web of Science ®Google Scholar